No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ONCY Oncolytics Biotech
- 1.030
- +0.020+1.98%
Close Jul 5 16:00 ET
- 1.030
- 0.0000.00%
Post 19:55 ET
78.13MMarket Cap-3503P/E (TTM)
1.040High0.990Low129.67KVolume0.990Open1.010Pre Close131.24KTurnover0.18%Turnover RatioLossP/E (Static)75.85MShares3.37052wk High4.62P/B74.80MFloat Cap0.88352wk Low--Dividend TTM72.62MShs Float7.400Historical High--Div YieldTTM4.95%Amplitude0.351Historical Low1.012Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond
USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million...
Oncolytics Biotech Advances Breast Cancer Trial With FDA Support
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from it
Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on Its Metastatic Breast Cancer Program
07:00 AM EDT, 06/27/2024 (MT Newswires) -- Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Oncolytics Biotech Chair Wayne Pisano To Serve As Interim CEO As Dr. Matt Coffey Looks To Take Medical Leave Of Absence
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive
Maxim Group Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Maxim Group analyst Jason McCarthy maintains $Oncolytics Biotech(ONCY.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 24.0% a
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike
USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...
Comments
$Oncolytics Biotech(ONCY.US$ Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on Its Metastatic Breast Cancer Program
MT Newswires· 12 mins ago
07:00 AM EDT, 06/27/2024 (MT Newswires) -- Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
MT Newswires· 12 mins ago
07:00 AM EDT, 06/27/2024 (MT Newswires) -- Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
$Oncolytics Biotech(ONCY.US$
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech has dosed the first patient in the GOBLET study cohort, which assesses the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The study, funded by a US$5 million grant from PanCAN’s Therapeutic Accelerator Awar...
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech has dosed the first patient in the GOBLET study cohort, which assesses the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The study, funded by a US$5 million grant from PanCAN’s Therapeutic Accelerator Awar...
3
$Oncolytics Biotech(ONCY.US$ A Type C meeting with the Food and Drug Administration in the coming few weeks will establish registrational pathway for Oncolytic Biotech's pelareorep in HR+/HER2- metastatic breast cancer, notes RBC.
Following discussions with the clinical advisors, collaborators, and potential partners over the last year, Oncolytics aims to conduct an "efficiently sized," cost-effective, randomized, controlled study that with positive data could lead directly to a...
Following discussions with the clinical advisors, collaborators, and potential partners over the last year, Oncolytics aims to conduct an "efficiently sized," cost-effective, randomized, controlled study that with positive data could lead directly to a...
1
$Oncolytics Biotech(ONCY.US$
NEWS
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expecte...
NEWS
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expecte...
$Oncolytics Biotech(ONCY.US$ You were supposed to drop after my post! Not go up a bit! Grrrr! Hehehe
2
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg